RECRUITING

Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial evaluates whether a network of peer genetic coaches is useful for addressing disparities in genetic testing and screening among African American men with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). While genetic testing has become central to prostate cancer care, African American men are less likely seek testing due to lack of awareness, cultural beliefs, financial limitations, fear of discrimination, and mistrust in the healthcare system. A network of peer genetic coaches may help address barriers, beliefs, and needs of African American men in the community and provide navigation to increase engagement in genetic testing.

Official Title

Peer Genetic Coaches for Enhancing Genetic Testing Awareness, Navigation, and Delivery Among African American Men With Metastatic Prostate Cancer, The EXPAND Network

Quick Facts

Study Start:2024-06-03
Study Completion:2026-04-29
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05627219

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * AIM 1: Are 18 years old or older
  2. * AIM 1: Are able to read and speak English comfortably
  3. * AIM 1: Men who have experience with both prostate cancer (PCA) and genetic counseling and testing will be a priority for training, as well as men who have considerable peer education or navigation experience
  4. * AIM 2: Are 18 years old or older
  5. * AIM 2: Are African American
  6. * AIM 2: Are able to read and speak English comfortably
  7. * AIM 2: Men who meet any one of the following criteria: (1) metastatic prostate cancer; (2) prostate cancer with high-risk features (T3 or higher, Gleason 8 or higher, node positive disease); (3) with or without a diagnosis of prostate cancer with strong family history (2 or more first-degree or second-degree relatives) with prostate cancer (particularly metastatic prostate cancer or died from prostate cancer), breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, uterine cancer, renal cancer, urothelial cancer, or upper bowel cancer
  1. * Patients that do not meet the inclusion criteria
  2. * Children under the age of 18
  3. * Anyone who has trouble understanding the consent or with significant anxiety detected during the consent process

Contacts and Locations

Study Contact

Amy Leader, DrPh, MPH
CONTACT
215 955-7739
amy.leader@jefferson.edu

Principal Investigator

Amy Leader, DrPh, MPH
PRINCIPAL_INVESTIGATOR
Thomas Jefferson University

Study Locations (Sites)

Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
United States

Collaborators and Investigators

Sponsor: Thomas Jefferson University

  • Amy Leader, DrPh, MPH, PRINCIPAL_INVESTIGATOR, Thomas Jefferson University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-03
Study Completion Date2026-04-29

Study Record Updates

Study Start Date2024-06-03
Study Completion Date2026-04-29

Terms related to this study

Additional Relevant MeSH Terms

  • Metastatic Prostate Carcinoma
  • Stage IIIB Prostate Cancer AJCC v8
  • Stage IIIC Prostate Cancer AJCC v8
  • Stage IV Prostate Cancer AJCC v8